Tumor-derived Semaphorin 4A Improves PD-1–blocking Antibody Efficacy by Enhancing CD8 + T Cell Cytotoxicity and Proliferation
Yujiro Naito,Shohei Koyama,Kentaro Masuhiro,Takashi Hirai,Takeshi Uenami,Takako Inoue,Akio Osa,Hirotomo Machiyama,Go Watanabe,Nicolas Sax, Jordan Villa,Yumi Kinugasa-Katayama,Satoshi Nojima,Moto Yaga,Yuki Hosono,Daisuke Okuzaki,Shingo Satoh,Takeshi Tsuda,Yoshimitsu Nakanish,Yasuhiko Suga, Takayosh Morita,Kiyohar Fukushima,Masayuk Nishide,Takayuki Shiroyama,Kotaro Miyake,Kota Iwahori,Haruhiko Hirata,Izumi Nagatomo,Yukihiro Yano,Motohiro Tamiya,Toru Kumagai,Norihiko Takemoto,Hidenori Inohara,Sho Yamasaki,Kazuo Yamashita,Taiki Aoshi,Esra A. Akbay,Naoki Hosen,Yasush Shintani,Hyota Takamatsu,Masahide Mori,Yoshito Takeda,Atsushi Kumanogoh SCIENCE ADVANCES（2023）
Key words
Immune Regulation,Cancer Immunotherapy,Cell Signaling,Semaphorins
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper